Cargando…

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease

BACKGROUND & AIM: We studied FibroTouch (FT) and Fibroscan (FS) examination results and their repeatability when performed by healthcare personnel of different background. METHODS: FT and FS examinations were performed on patients with chronic liver disease by two operators, a doctor and a nurse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Ying Zhuang, Lai, Lee Lee, Wong, Sui Weng, Mohamad, Siti Yatimah, Chuah, Kee Huat, Chan, Wah Kheong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092664/ https://www.ncbi.nlm.nih.gov/pubmed/33939744 http://dx.doi.org/10.1371/journal.pone.0250300

Ejemplares similares

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra, Joao Tiago, et al.
Publicado: (2020)

Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Qu, Ying, et al.
Publicado: (2021)

Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch
por: Liao, Yan, et al.
Publicado: (2023)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Chuah, Kee-Huat, et al.
Publicado: (2023)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study
por: Zuo, Zhongbao, et al.
Publicado: (2022)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients
por: Deng, Hong, et al.
Publicado: (2016)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
por: Jun, Baek Gyu, et al.
Publicado: (2017)

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease
por: Wilder, Julius, et al.
Publicado: (2014)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
por: Chan, Yin, et al.
Publicado: (2017)

Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan(®)) before curative resection of hepatocellular carcinoma: a pilot study
por: Kim, Seung Up, et al.
Publicado: (2008)

Correlates of hepatic stiffness by FibroScan(©) in a multicentric Italian cohort of HIV-infected patients
por: Tarquini, P, et al.
Publicado: (2010)

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
por: Wong, Stephanie, et al.
Publicado: (2017)

Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
por: Oeda, Satoshi, et al.
Publicado: (2020)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
por: Durango, Esteban, et al.
Publicado: (2013)

Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
por: Maklad, Sahar, et al.
Publicado: (2014)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
por: Sanyal, Arun J., et al.
Publicado: (2023)

Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation
por: Kim, Seung Up, et al.
Publicado: (2012)

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
por: Eris, Tansu, et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
por: Chan, Wah-Kheong, et al.
Publicado: (2023)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
por: Chan, Wah-Loong, et al.
Publicado: (2023)

Laboratory Tests, Liver Vessels Color Doppler Sonography, and FibroScan Findings in Patients with Nonalcoholic Fatty Liver Disease: An Observation Study
por: Alizadeh, Ahmad, et al.
Publicado: (2018)

Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection
por: Huang, Ling-Ling, et al.
Publicado: (2021)

Points to Be Considered When Applying FibroScan S Probe in Children With Biliary Atresia
por: Kim, Seung, et al.
Publicado: (2014)

Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy
por: Malekzadeh, Reza, et al.
Publicado: (2011)

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
por: Hsu, Po-Ke, et al.
Publicado: (2021)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023)

Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls
por: Jiang, Kaiping, et al.
Publicado: (2022)

The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan(®) CAP Values among the Taiwanese Population
por: Lee, Meng-Szu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0su549mvtgplbtev0o5edil3dq